Glaucoma, Open-Angle Clinical Trial
Official title:
Evaluating Effectiveness of Home Testing Devises for Assisting in Management of Glaucoma Outside a Clinical Setting During a 2 Year Period.
With the advancement in technology we have the opportunity of performing the glaucoma testing at home to monitor the disease. The purpose of this study is evaluating the feasibility and patient acceptance of home testing with head mounted perimetry; detection of progression with head mounted perimetry vs office based perimetry; and monitoring the eye pressure measured by patients at home using a portable tonometer.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age 20-80 years 2. Mild and Moderate Open Angle Glaucoma (OAG) 3. Refraction under 12.00 diopter of spherical refractive error and astigmatism of less than 2.5 diopter. Exclusion Criteria: 1. Spherical refraction outside > ± 12.00 D and cylinder correction > +2.5 D. 2. Visual acuity worse than 20/50 either eye 3. Cataract surgery with or without Minimally Invasive Glaucoma Surgery (MIGS) less than 90 days prior to enrollment 4. Filtering surgeries less than 6 months prior to enrollment 5. Intraocular surgery other than: 1. Non-complicated MIGS more than 90 days prior to enrollment; 2. Cataract or refractive surgery performed more than 90 days before enrollment and without posterior capsule opacification 3. Other glaucoma surgery more than 6 months prior to enrollment. 6. History of systemic or ocular condition (other than glaucoma or mild to moderate cataract) known to affect visual function. 7. History of medication known to affect visual function or influence patient reaction time 8. Inability to use device after remote training session 9. Subjects unwilling and/or unable to participate |
Country | Name | City | State |
---|---|---|---|
United States | Wills Eye Hospital | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Wills Eye |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Retinal Nerve Fiber Layer (RNFL) Thickness | Retinal Nerve Fiber Layer (RNFL) Thickness in microns will be obtained by a computerized picture without touching the eye with Spectralis (Zeiss) Optical Coherence Tomography (OCT) at baseline and then yearly during a 2 year period. | 10 minutes, 3 times for 2 years | |
Primary | Change in Visual Field Mean Deviation with VisuALL | The visual field measures sensitivity of the retina to light at several locations in the peripheral vision. The difference of mean of these measurements compared to a normal database is presented in negative or positive values called mean deviation.
Visual field mean deviation (MD) (light measurement in decibels in multiple spots across the central and peripheral retina known as entire visual field) will be captured by VisuALL per eye once a week during a 2 year period at participant's home. |
12 minutes each week for 104 weeks | |
Primary | Change in Intraocular Pressure with iCare | Intraocular pressure, measured in millimeters of mercury (mmHG), will be measured by patients using a device called iCare Home Tonometer, specifically designed for patients to measure their eye pressures at home. They will measure eye pressure of each eye 3 times a day for 7 days every 3 months during a 2 year period at participant's home. | 15 minutes daily over 1 week, 8 times for 2 years | |
Secondary | Change in Visual Field Mean Deviation with Humphrey Field Analyzer | The visual field measures sensitivity of the retina to light at several locations in the peripheral vision. The difference of mean of these measurements compared to a normal database is presented in negative or positive values called mean deviation.
Visual field mean deviation (MD) (light measurement in decibels in multiple spots across the central and peripheral retina known as entire visual field) will be measured in the office by Humphrey perimeter 24-2 SITA standard per 3 times at baseline and then every 6 months during a 2 year period.. |
2 hours, 5 times for 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05044793 -
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
|
||
Recruiting |
NCT06201455 -
Evaluation of Phacogoniotomy in Medically-controlled POAG
|
N/A | |
Recruiting |
NCT03369886 -
The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI
|
N/A | |
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Recruiting |
NCT02679482 -
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01489670 -
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A | |
Completed |
NCT00693485 -
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
|
Phase 2 | |
Completed |
NCT00753168 -
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
|
Phase 1/Phase 2 | |
Completed |
NCT00051194 -
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
|
Phase 2 | |
Recruiting |
NCT04920227 -
Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma
|
N/A | |
Active, not recruiting |
NCT03868124 -
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
|
Phase 3 | |
Completed |
NCT03267862 -
Scleral Response to Intraocular Pressure (IOP)
|
N/A | |
Recruiting |
NCT06066645 -
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
|
Phase 3 | |
Recruiting |
NCT04912362 -
The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04949802 -
Glaucoma Surgery Using the ViaLase Laser System
|
N/A | |
Recruiting |
NCT04038034 -
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04632329 -
Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma
|
N/A | |
Completed |
NCT01215786 -
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
|
Phase 1 |